Literature DB >> 23711285

Comparison of two low-dose calcium infusion schedules for localization of insulinomas by selective pancreatic arterial injection with hepatic venous sampling for insulin.

G Braatvedt1, E Jennison, I M Holdaway.   

Abstract

OBJECTIVE: Localization of small insulinomas may be difficult. Selective pancreatic arterial injection of calcium with hepatic venous insulin measurement (SACST) has been used for this purpose, but can rarely cause hypoglycaemia. Two low-dose concentrations of calcium, 0·25 and 0·1 of the usual concentration used for the test, have been compared for sensitivity of localization and safety.
DESIGN: Selective pancreatic arterial injection of calcium with hepatic venous insulin measurement was performed at calcium concentrations of 0·0025 (Protocol A) and 0·00625 (Protocol B) mEq calcium per kg. The standard concentration is 0·025 mEq/kg. PATIENTS: Twenty one successive patients with biochemical evidence of insulinoma were studied.
RESULTS: Using surgical localization as the gold standard, Protocol A had a sensitivity of 91% and Protocol B 75% for correct localization. The false-positive localization rate was 16%. No hypoglycaemia was observed. These results compare favourably with published data using the standard calcium concentration. Selective pancreatic arterial injection of calcium with hepatic venous insulin measurement was superior to localization by noninvasive imaging; in seven cases, SACST was correct when conventional imaging was negative (five) or false positive (two).
CONCLUSION: Low concentrations of calcium are effective and safe when performing SACST for localization of insulinoma.
© 2013 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23711285     DOI: 10.1111/cen.12253

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  5 in total

1.  ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors.

Authors:  M Falconi; B Eriksson; G Kaltsas; D K Bartsch; J Capdevila; M Caplin; B Kos-Kudla; D Kwekkeboom; G Rindi; G Klöppel; N Reed; R Kianmanesh; R T Jensen
Journal:  Neuroendocrinology       Date:  2016-01-05       Impact factor: 4.914

2.  Characteristics and Outcomes of 79 Patients with an Insulinoma: A Nationwide Retrospective Study in Finland.

Authors:  Elina Peltola; Päivi Hannula; Heini Huhtala; Saara Metso; Ulla Kiviniemi; Martine Vornanen; Juhani Sand; Johanna Laukkarinen; Mirja Tiikkainen; Camilla Schalin-Jäntti; Johanna Arola; Jukka Sirén; Antti Piiroinen; Minna Soinio; Pirjo Nuutila; Mirva Söderström; Hanna Hämäläinen; Leena Moilanen; David Laaksonen; Elina Pirinen; Fia Sundelin; Tapani Ebeling; Pasi Salmela; Markus J Mäkinen; Pia Jaatinen
Journal:  Int J Endocrinol       Date:  2018-10-23       Impact factor: 3.257

3.  Diagnostic value of ASVS for insulinoma localization: A systematic review and meta-analysis.

Authors:  Hao Wang; Ying Ba; Qian Xing; Run-Ce Cai
Journal:  PLoS One       Date:  2019-11-19       Impact factor: 3.240

4.  Low-dose Selective Arterial Calcium Stimulation Test for Localizing Insulinoma: A Single-center Experience of Five Consecutive Cases.

Authors:  Tomonobu Hatoko; Takaaki Murakami; Masakatsu Sone; Daisuke Yabe; Toshihiko Masui; Yuji Nakamoto; Akihiro Furuta; Norimitsu Uza; Yuzo Kodama; Norio Harada; Masahito Ogura; Akihiro Yasoda; Nobuya Inagaki
Journal:  Intern Med       Date:  2020-06-30       Impact factor: 1.271

Review 5.  Surgical Management of Neuroendocrine Tumours of the Pancreas.

Authors:  Regis Souche; Christian Hobeika; Elisabeth Hain; Sebastien Gaujoux
Journal:  J Clin Med       Date:  2020-09-16       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.